Focus: Cancer Center Featured Story 2

• share
• favorite_border

• share
• favorite_border

The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading academic cancer centers in the United States—is celebrating six years of working alongside the African Cancer Coalition (ACC), the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI), as part of Allied Against Cancer.

• share
• favorite_border

Dozens of eye drop recalls this year have left consumers confused about product safety. An expert explains why there have been so many recalls and how to pick safe eye drops.

• share
• favorite_border

The Cancer Research Institute and Lance Kawaguchi with the #SouthPoleTrek4Cancer ring in the Nasdaq Stock Market Closing Bell.

• share
• favorite_border

The National Comprehensive Cancer Network’s Oncology Research Program selects projects to evaluate the effectiveness of elranatamab in the treatment of multiple myeloma.

• share
• favorite_border

Nidhi Sahni, Ph.D., associate professor of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center, has been awarded the 2024 Mary Beth Maddox Award and Lectureship in cancer research from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

• share
• favorite_border

The University of New Mexico Comprehensive Cancer Center is expanding its clinical space to offer treatments that no other entity in the state can offer.

• share
• favorite_border

Moffitt Cancer Center researchers are working to better understand the molecular mechanisms that promote the development and progression of breast cancer brain metastasis to help improve diagnostics and treatments. In a new study published in the December issue of Cell Reports, they report on identifying a cell signaling pathway that controls breast cancer brain metastasis.

• share
• favorite_border

UC Davis researchers are recruiting infants ages 6-12 months for a new national telehealth study aimed at understanding which developmental delays could indicate autism or other conditions.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

• share
• favorite_border

The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) today announced the largest single donation in its nearly 150-year history, a $400 million gift from Kenneth C. Griffin, Founder and Chief Executive Officer of Citadel and Founder of Griffin Catalyst, and David Geffen, Founder of The David Geffen Foundation.

• share
• favorite_border

New research results in JNCCN are encouraging regarding the benefit of immunotherapy for treating lung cancer across racial and ethnic groups, but also reinforce need to include more Black and Hispanic people in cancer clinical trials and highlight the importance of equitable treatment delivery for closing disparities in outcomes.

• share
• favorite_border

A study in Psychology of Addictive Behaviors finds teens who have more demand for cannabis are likely to use it for enjoyment and coping. Understanding motives is important for addiction prevention.

• share
• favorite_border

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis.

• share
• favorite_border

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.

• share
• favorite_border

MD Anderson and Rigel Pharmaceuticals announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia and other hematologic cancers.

• share
• favorite_border

The targeted therapy trastuzumab deruxtecan (T-Dxd), an antibody drug conjugate, is now an approved treatment of HER2-low advanced breast cancers. In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.

• share
• favorite_border

CRI's 2023 Patient Immunotherapy Summit is now available on-demand for the benefit of cancer patients, families, caregivers, and scientists.

• share
• favorite_border

Patients with sickle cell disease (SCD) often face a reduced quality of life and a lower life expectancy. Allotransplantation, the first treatment for SCD with curative potential, comes with risks, including transplant-related mortality. Gene therapy, once approved for SCD, could also offer a lifelong cure without the risk associated with allotransplantation.

• share
• favorite_border

In a new study published in the Journal for ImmunoTherapy of Cancer, a team of researchers from the Donald A. Adam Melanoma and Skin Cancer Center of Excellence at Moffitt Cancer Center reveals differences in the mechanisms of action of two FDA-approved immune checkpoint inhibitor combination therapies for advanced melanoma.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

NCCN—an alliance of leading cancer centers—hosted a Patient Advocacy Summit to explore the role of navigation throughout the cancer process. A diverse group of subject matter experts addressed the impact patient navigation has on care and how to utilize navigators to reduce economic burdens and disparities in care.

• share
• favorite_border

Three physician-scientists who have relocated to Buffalo, New York, to join Roswell Park Comprehensive Cancer Center will apply highly specialized transplantation and cell therapy (TCT) expertise to both patient care and the development of New York State’s first cell therapy manufacturing and research hub. Brian Betts, MD, has joined Roswell Park as Vice Chair of Strategic Initiatives within the Transplant & Cellular Therapy Section, Department of Medicine; Kanwaldeep Mallhi, MD, was named Associate Professor of Oncology and Clinical Director of Pediatric Transplantation and Cellular Therapy in the Department of Pediatrics; and Shernan Holtan, MD, will join the Roswell Park faculty in February as Chief of Blood and Marrow Transplant in the Department of Medicine.

• share
• favorite_border

Two antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), were approved by the FDA to treat metastatic breast cancers. ADCs are a type of targeted therapy that release cancer drugs to specific tumor cells. The efficacy of T-DXd and SG depends on target expression and the best method for measuring that expression is still not known.

• share
• favorite_border

Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy at The University of Texas MD Anderson Cancer Center, has been honored with the E. Donnall Thomas Lecture and Prize from the American Society of Hematology (ASH, for her groundbreaking research to develop and advance innovative cell therapies for cancer using natural killer (NK) cells.

• share
• favorite_border

Based on the results from this phase III trial, Yale Cancer Center expert Dr. Amer Zeidan says imetelstat, a first-in-class telomerase inhibitor, leads to durable red blood cell transfusion independence and a significant improvement in anemia in heavily transfused lower risk MDS patients.

• share
• favorite_border

Incorporating navy beans into the diet of colorectal cancer survivors has the potential to positively impact both gut and host health by modulating markers linked to obesity and disease, according to new research from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

Researchers at the UC Davis Comprehensive Cancer Center have discovered that using gene therapy to inhibit a specific protein, galectin 1, can shrink liver cancer tumors in an animal model.

• share
• favorite_border

SEATTLE — Nov. 30, 2023 — The 65th Annual Meeting & Exposition of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 9-13.Below are highlights of Fred Hutchinson Cancer Center research to be presented and experts available to comment on news.

• share
• favorite_border

George Demetri, MD, director of the Sarcoma Center at Dana-Farber Cancer Institute, is being awarded the prestigious J.E. Wallace Sterling Lifetime Achievement Award in Medicine from the Stanford Medicine Alumni Association (SMAA).

• share
• favorite_border

The Latin American and Caribbean Society of Medical Oncology (SLACOM) and National Comprehensive Cancer Network (NCCN) host the Latin American Regional Breast Cancer Summit: Advocating and Implementing Guideline-Concordant Cancer Care for Patients. Esteemed experts from Argentina, Brazil, Mexico, Columbia, Peru, and the United States present challenges, barriers, and potential solutions for improving access to guideline-concordant breast cancer care in the Latin American region.

• share
• favorite_border

Moffitt Cancer Center has received a $3.6 million grant from the National Institute of Dental and Craniofacial Research (U01DE033329) to further groundbreaking research that has unveiled a promising noninvasive diagnostic biomarker panel for the early detection of oropharyngeal cancer.

• share
• favorite_border

Yale Cancer Center researchers at Yale School of Medicine will present new research at the 46th annual San Antonio Breast Cancer Symposium (SABCS) from December 5 to 9. The international symposium provides leading-edge breast cancer information on prevention, etiology, diagnosis, and therapy as well as experimental biology. This year’s symposium, at the Henry B.

• share
• favorite_border

Researchers in Moffitt Cancer Center’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence have been working to better understand what drives melanoma brain metastasis.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) and NMDP/Be The Match® today announced the launch of the “American Symphony: Become a Lifesaver” campaign to increase registration of blood stem cell and marrow donors to the national registry and improve access to blood stem cell transplants.

• share
• favorite_border

A new Phase Ib/II study from researchers at The University of Texas MD Anderson Cancer Center and Moffitt Cancer Center found that combining sensitizing drugs with a specific form of radiation therapy may be more effective in patients with locally advanced pancreatic cancer, yielding a higher progression-free survival (PFS) and overall response rate (ORR).

• share
• favorite_border

Physicians and scientists from Yale Cancer Center, part of Yale School of Medicine, will present new research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif., from December 9 to 12. This year’s ASH meeting will include oral and poster presentations, workshops, and educational sessions for hematology professionals.

• share
• favorite_border

Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present an extensive array of hematology/oncology data from their clinical research program at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in San Diego, California (and virtually) from December 9-12, 2023.

• share
• favorite_border

Robert A. Winn, MD, president of the Association of American Cancer Institutes (AACI) and director of VCU Massey Comprehensive Cancer Center, has appointed two community advocates to the steering committee of his AACI presidential initiative, Inclusive Excellence.

• share
• favorite_border

DNA fragments circulating in patients’ blood can reveal the presence of tumors long before CT scans and lead to more agile use of cancer drugs.

• share
• favorite_border

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced grants awarded for developing innovative investigator-initiated research involving the medication relugolix.

• share
• favorite_border

The Association of American Cancer Institutes (AACI) supports President Biden’s nomination of W. Kimryn Rathmell, MD, PhD, MMHC, as the next director of the National Cancer Institute (NCI).

• share
• favorite_border

Akshu Balwan, MD, breathes easier these days because The University of New Mexico Comprehensive Cancer Center launched a new comprehensive lung cancer screening clinic as part of the institution's lung cancer screening program.

• share
• favorite_border

Patients with advanced prostate cancer with tumors harboring RB1 gene loss or neuroendocrine features often have a poor prognosis and limited treatment options.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

• share
• favorite_border

A phase 1 clinical trial conducted exclusively at Roswell Park Comprehensive Cancer Center shows that a novel treatment regimen can make immunotherapy more effective in patients with metastatic triple-negative breast cancer (mTNBC).

• share
• favorite_border

The James P. Allison Institute at MD Anderson hosted its inaugural scientific symposium on Nov. 10, bringing together more than 400 leading scientists in immunotherapy and immunobiology.